AN2 Therapeutics (ANTX) Prepaid Assets (2021 - 2026)
AN2 Therapeutics (ANTX) reported Prepaid Assets of $2.2 million for Q1 2026, down 11.84% year-over-year from $2.5 million in Q1 2025, and up 13.79% quarter-over-quarter from $1.9 million in Q4 2025.
AN2 Therapeutics (ANTX) Prepaid Assets (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Prepaid Assets data on file, last reported at $2.2 million in Q1 2026.
- Prepaid Assets for Q1 2026 came in at $2.2 million, down 11.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (down 11.84% YoY), and the FY2025 annual result was $1.9 million, down 26.78% from the prior year.
- Prepaid Assets improved to $2.2 million in Q1 2026 per ANTX's latest filing, from $1.9 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.6 million in Q2 2025 and troughed at $1.4 million in Q1 2022.
- A 5-year average of $2.7 million and a median of $2.6 million in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets jumped 64.53% in 2024, then tumbled 50.86% in 2025.
- A 5-year view of Prepaid Assets shows it stood at $2.5 million in 2022, then rose by 28.02% to $3.2 million in 2023, then decreased by 17.68% to $2.6 million in 2024, then slipped by 26.78% to $1.9 million in 2025, then increased by 13.79% to $2.2 million in 2026.
- Business Quant data shows ANTX's Prepaid Assets at $2.2 million in Q1 2026, $1.9 million in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 1.94 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Sep 30, 2024 | 4.26 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 3.21 Mn |
| Sep 30, 2023 | 2.59 Mn |
| Jun 30, 2023 | 2.94 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Dec 31, 2022 | 2.51 Mn |
| Sep 30, 2022 | 2.84 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 1.55 Mn |